Correlation Between Elevation Oncology and Recursion Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Elevation Oncology and Recursion Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Elevation Oncology and Recursion Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Elevation Oncology and Recursion Pharmaceuticals, you can compare the effects of market volatilities on Elevation Oncology and Recursion Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Elevation Oncology with a short position of Recursion Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Elevation Oncology and Recursion Pharmaceuticals.

Diversification Opportunities for Elevation Oncology and Recursion Pharmaceuticals

0.28

Correlation Coefficient

Elevation Oncology  Recursion Pharmaceuticals

Modest diversification

The 3 months correlation between Elevation and Recursion is 0.28. Overlapping area represents the amount of risk that can be diversified away by holding Elevation Oncology and Recursion Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Recursion Pharmaceuticals and Elevation Oncology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Elevation Oncology are associated (or correlated) with Recursion Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Recursion Pharmaceuticals has no effect on the direction of Elevation Oncology i.e., Elevation Oncology and Recursion Pharmaceuticals go up and down completely randomly.

Pair Corralation between Elevation Oncology and Recursion Pharmaceuticals

Given the investment horizon of 90 days Elevation Oncology is expected to under-perform the Recursion Pharmaceuticals. In addition to that, Elevation Oncology is 1.06 times more volatile than Recursion Pharmaceuticals. It trades about -0.02 of its total potential returns per unit of risk. Recursion Pharmaceuticals is currently generating about 0.1 per unit of volatility. If you would invest  617.00  in Recursion Pharmaceuticals on September 5, 2024 and sell it today you would earn a total of  141.00  from holding Recursion Pharmaceuticals or generate 22.85% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	98.44%
Values	Daily Returns

Elevation Oncology  vs.  Recursion Pharmaceuticals

Elevation Oncology

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Elevation Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest conflicting performance, the Stock's technical and fundamental indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Recursion Pharmaceuticals

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Recursion Pharmaceuticals are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, Recursion Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Elevation Oncology and Recursion Pharmaceuticals

The main advantage of trading using opposite Elevation Oncology and Recursion Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Elevation Oncology position performs unexpectedly, Recursion Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Recursion Pharmaceuticals will offset losses from the drop in Recursion Pharmaceuticals' long position.

The idea behind Elevation Oncology and Recursion Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.